Drug Ther Bull. 2007 Nov;45(11):81-5. doi: 10.1136/dtb.2007.10.0002.
Around 800,000 people in the UK have dementia, about 80% of whom will have behavioural changes or psychological symptoms in the course of the illness. Such features lower quality of life for both patients and carers, and often result in transfer to residential care and higher costs. Currently, no drugs are licensed in the UK specifically for behavioural changes and psychological symptoms in patients with dementia. Nevertheless, antipsychotic medications have been used in people with dementia, both for psychotic symptoms and also for less specific problems such as agitation and aggression. There have been long-standing concerns about the inappropriate use of these drugs in such settings. In 2004, following worries over an increased likelihood of stroke with risperidone and olanzapine, the former UK Committee on Safety of Medicines (CSM) advised that these drugs "should not be used for the treatment of behavioural symptoms of dementia". However, this led to reports of unsuitable interpretation of the guidance, with groups of patients having their medication withdrawn inappropriately or being switched to other, potentially more harmful, drugs. Here we assess the safety of antipsychotic medication in people with dementia.
在英国,约有80万人患有痴呆症,其中约80%的人在患病过程中会出现行为改变或心理症状。这些症状会降低患者和护理人员的生活质量,常常导致患者被送往养老院,并产生更高的费用。目前,在英国没有专门获批用于治疗痴呆症患者行为改变和心理症状的药物。尽管如此,抗精神病药物已被用于痴呆症患者,既用于治疗精神病性症状,也用于治疗一些不太特定的问题,如激越和攻击行为。长期以来,人们一直担心这些药物在这种情况下的不当使用。2004年,鉴于对使用利培酮和奥氮平会增加中风风险的担忧,英国药品安全委员会(CSM)曾建议,这些药物“不应被用于治疗痴呆症的行为症状”。然而,这导致了对该指南的不当解读报告,一些患者群体的药物被不恰当地停用,或者被换成其他可能更有害的药物。在此,我们评估抗精神病药物在痴呆症患者中的安全性。